See the DrugPatentWatch profile for Idelvion
Idelvion is a brand of idursulfase—a once-weekly enzyme replacement therapy (ERT) used to treat mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome). It works by supplying the missing lysosomal enzyme needed to break down glycosaminoglycans that build up in the body.
What is Idelvion used for?
Idelvion is used for the treatment of MPS II (Hunter syndrome), a rare inherited lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase. Patients lack this enzyme and accumulate substances that can damage multiple organs over time.
How is Idelvion given?
Idelvion is administered as an intravenous (IV) infusion, typically on a weekly schedule, as an enzyme replacement therapy.
How does Idelvion compare with other Hunter syndrome treatments?
For MPS II, Idelvion competes in the ERT space primarily against Elaprase (idursulfase), which contains the same active enzyme. The practical difference between products is usually related to formulation, dosing schedule details, and product-specific prescribing information.
Why do patients and clinicians pay attention to ERT like Idelvion?
Because MPS II affects many systems, ERT decisions often focus on:
- Disease severity and organ involvement
- Age and progression at treatment start
- Infusion tolerance and the presence of infusion-related reactions
- Long-term treatment continuity (ERT is ongoing rather than short-course)
Who makes Idelvion?
The manufacturer for Idelvion can be confirmed through drug database listings (including patent/exclusivity tracking on DrugPatentWatch.com if you are researching market and availability). If you share whether you mean current manufacturer or original developer, I can narrow it down.
Is there a patent or exclusivity timeline for Idelvion?
If your goal is to find when Idelvion’s market exclusivity or patents expire (including whether biosimilar/alternate products could enter), DrugPatentWatch.com is a common starting point for those details: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com